Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: experience from a pediatric case series

J Chemother. 2012 Aug;24(4):243-4. doi: 10.1179/1973947812Y.0000000012.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Amphotericin B / administration & dosage*
  • Amphotericin B / adverse effects
  • Amphotericin B / therapeutic use
  • Antibiotic Prophylaxis* / adverse effects
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / adverse effects
  • Antifungal Agents / therapeutic use
  • Child
  • Child, Preschool
  • Early Termination of Clinical Trials
  • Female
  • Hospitals, Pediatric
  • Humans
  • Immunocompromised Host*
  • Liposomes
  • Lung Diseases, Fungal / immunology
  • Lung Diseases, Fungal / prevention & control
  • Male
  • Mycoses / immunology
  • Mycoses / prevention & control*
  • Time Factors

Substances

  • Antifungal Agents
  • Liposomes
  • Amphotericin B